JP2008537673A5 - - Google Patents

Download PDF

Info

Publication number
JP2008537673A5
JP2008537673A5 JP2007553371A JP2007553371A JP2008537673A5 JP 2008537673 A5 JP2008537673 A5 JP 2008537673A5 JP 2007553371 A JP2007553371 A JP 2007553371A JP 2007553371 A JP2007553371 A JP 2007553371A JP 2008537673 A5 JP2008537673 A5 JP 2008537673A5
Authority
JP
Japan
Prior art keywords
antibody
ephb2
seq
hvr
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007553371A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008537673A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2006/003502 external-priority patent/WO2006083936A2/en
Publication of JP2008537673A publication Critical patent/JP2008537673A/ja
Publication of JP2008537673A5 publication Critical patent/JP2008537673A5/ja
Pending legal-status Critical Current

Links

JP2007553371A 2005-01-31 2006-01-31 抗ephb2抗体とその使用方法 Pending JP2008537673A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US64854105P 2005-01-31 2005-01-31
US75684406P 2006-01-05 2006-01-05
PCT/US2006/003502 WO2006083936A2 (en) 2005-01-31 2006-01-31 Anti-ephb2 antibodies and methods using same

Publications (2)

Publication Number Publication Date
JP2008537673A JP2008537673A (ja) 2008-09-25
JP2008537673A5 true JP2008537673A5 (https=) 2009-02-26

Family

ID=36341431

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007553371A Pending JP2008537673A (ja) 2005-01-31 2006-01-31 抗ephb2抗体とその使用方法

Country Status (7)

Country Link
US (2) US7767205B2 (https=)
EP (1) EP1844076A2 (https=)
JP (1) JP2008537673A (https=)
AU (1) AU2006210837B2 (https=)
CA (1) CA2594636A1 (https=)
NZ (1) NZ556317A (https=)
WO (1) WO2006083936A2 (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1545613T1 (sl) 2002-07-31 2011-11-30 Seattle Genetics Inc Avristatinski konjugati in njihova uporaba za zdravljenje raka avtoimunske bolezni ali infekcijskebolezni
US7498298B2 (en) 2003-11-06 2009-03-03 Seattle Genetics, Inc. Monomethylvaline compounds capable of conjugation to ligands
WO2006132670A2 (en) 2004-11-12 2006-12-14 Seattle Genetics, Inc. Auristatins having an aminobenzoic acid unit at the n terminus
EP1833996B1 (en) * 2005-01-06 2012-12-05 Genentech, Inc. Cancer prognostic methods
US8871720B2 (en) 2005-07-07 2014-10-28 Seattle Genetics, Inc. Monomethylvaline compounds having phenylalanine carboxy modifications at the C-terminus
JP5171621B2 (ja) 2005-07-07 2013-03-27 シアトル ジェネティックス, インコーポレイテッド フェニルアラニン側鎖修飾をc末端に有するモノメチルバリン化合物
US7750116B1 (en) 2006-02-18 2010-07-06 Seattle Genetics, Inc. Antibody drug conjugate metabolites
EP2061510B1 (en) * 2006-08-31 2016-06-22 A.C.N. 135 493 391 Pty Ltd as trustee for Conca Unit Trust Treatment and/or prevention of barrett's esophagus using anti-ephb4 antibody-containing compositions
NZ583318A (en) 2007-07-16 2012-07-27 Genentech Inc Humanized anti-cd79b antibodies and immunoconjugates and methods of use
DK2474557T3 (da) 2007-07-16 2014-11-10 Genentech Inc Anti-CD79b-antistoffer og immunkonjugater og fremgangsmåder til anvendelse
US20090309617A1 (en) * 2007-08-24 2009-12-17 Ye Fang Biosensor antibody functional mapping
SG187517A1 (en) 2008-01-31 2013-02-28 Genentech Inc Anti-cd79b antibodies and immunoconjugates and methods of use
AU2010315008B2 (en) 2009-11-07 2015-12-03 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US9981046B2 (en) 2012-05-15 2018-05-29 Concortis Biosystems, Corp., a wholly owned Subsidiary of Sorrento Therapeutics, Inc. Drug-conjugates, conjugation methods, and uses thereof
WO2015057876A1 (en) 2013-10-15 2015-04-23 Sorrento Therapeutics Inc. Drug-conjugates with a targeting molecule and two different drugs
ES2826398T3 (es) 2013-10-15 2021-05-18 Seagen Inc Enlazadores-fármacos pegilados para una mejor farmacocinética de los conjugados ligando-fármaco
JP6590413B2 (ja) * 2014-02-06 2019-10-16 エックスフォー・ファーマシューティカルズ(オーストリア)ゲーエムべーハー 大腸菌特異的抗体配列
PT3262071T (pt) 2014-09-23 2020-06-16 H Hoffnabb La Roche Ag Métodos de utilização de imunoconjugados anti-cd79b
EP3250238B1 (en) 2015-01-28 2022-06-01 Sorrento Therapeutics, Inc. Antibody drug conjugates
WO2017089606A1 (en) * 2015-11-26 2017-06-01 Kotter Mark Reinhard Therapy to increase remyelination
US11793880B2 (en) 2015-12-04 2023-10-24 Seagen Inc. Conjugates of quaternized tubulysin compounds
CN108367043A (zh) 2015-12-04 2018-08-03 西雅图基因公司 季铵化的微管溶素化合物的缀合物
KR20180134351A (ko) 2016-03-25 2018-12-18 시애틀 지네틱스, 인크. 페길화된 약물-링커 및 그의 중간체의 제조를 위한 공정
US11046782B2 (en) 2016-03-30 2021-06-29 Musc Foundation For Research Development Methods for treatment and diagnosis of cancer by targeting glycoprotein A repetitions predominant (GARP) and for providing effective immunotherapy alone or in combination
AU2018237683A1 (en) 2017-03-24 2019-10-31 Seagen Inc. Process for the preparation of glucuronide drug-linkers and intermediates thereof
EP4168019A4 (en) * 2020-06-17 2024-07-31 4C Biomed Services Ltd. ANTIBODIES AGAINST EPHB2 AND ITS USE IN COMBINATION THERAPY
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5622701A (en) * 1994-06-14 1997-04-22 Protein Design Labs, Inc. Cross-reacting monoclonal antibodies specific for E- and P-selectin
IL156009A0 (en) * 2000-11-20 2003-12-23 California Inst Of Techn Artery smooth muscle and vein smooth muscle specific proteins and uses therefor
CA2633171C (en) * 2001-06-20 2012-11-20 Genentech, Inc. Antibodies against tumor-associated antigenic target (tat) polypeptides
ES2263984T3 (es) * 2002-06-28 2006-12-16 Domantis Limited Ligandos doble-especificos con una vida media serica aumentada.
CA2504042A1 (en) * 2002-11-05 2004-05-27 The Regents Of The University Of California Methods and materials for examining pathways associated with glioblastoma progression
US7498298B2 (en) * 2003-11-06 2009-03-03 Seattle Genetics, Inc. Monomethylvaline compounds capable of conjugation to ligands
WO2005101017A1 (en) * 2004-04-07 2005-10-27 Genentech, Inc. Mass spectrometry of antibody conjugates
EP1833996B1 (en) * 2005-01-06 2012-12-05 Genentech, Inc. Cancer prognostic methods

Similar Documents

Publication Publication Date Title
JP2008537673A5 (https=)
JP2008546780A5 (https=)
RU2423382C1 (ru) Композиции и способы диагностики и лечения опухоли
JP2014509835A5 (https=)
CN103517719B (zh) 抗体-药物缀合物
JP2013056896A5 (https=)
US10052382B2 (en) Methods for using antibodies for 3′ iso-LM1 and 3′, 6′-iso-LD1tumor gangliosides
HK1214161A1 (zh) 抗IL-13受体α2抗体和抗体-药物缀合物
JP2008529497A5 (https=)
JP2018534933A5 (https=)
JP2006507013A5 (https=)
IL290591B2 (en) Antibody drug preparations (ADC) that bind to 191P4D12 proteins
JP2017522861A5 (https=)
JP2014520088A5 (https=)
JP2010504755A5 (https=)
JP2018509146A (ja) Flt3タンパク質に結合する抗体薬物複合体(adc)
JP2014524902A5 (https=)
RU2007133108A (ru) АНТИТЕЛА, СВЯЗЫВАЮЩИЕСЯ С EphA2, И МЕТОДЫ ИХ ИСПОЛЬЗОВАНИЯ
JP2014531201A5 (https=)
HRP20180352T1 (hr) Protutijela anti-fcrh5
RU2015142815A (ru) Лечение рака с использованием антител, связывающихся с поверхностным grp78
JP2020522280A5 (https=)
JP2019205480A5 (https=)
RU2016118573A (ru) Анти-ly6e антитела и способы применения
JP2020522281A5 (https=)